The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
Open accessAbstract
Failure of immunization with the HIV-1 envelope to induce broadly neutralizing antibodies against conserved epitopes is a major barrier to producing a preventive HIV-1 vaccine. Broadly neutralizing monoclonal antibodies (BnAbs) from those subjects who do produce them after years of chronic HIV-1 infection have one or more unusual characteristics, including polyreactivity for host antigens, extensive somatic hypermutation and long, variable heavy-chain third complementarity-determining regions, factors that may limit their expression by host immunoregulatory mechanisms. The isolation of BnAbs from HIV-1–infected subjects and the use of computationally derived clonal lineages as templates provide a new path for HIV-1 vaccine immunogen design. This approach, which should be applicable to many infectious agents, holds promise for the construction of vaccines that can drive B cells along rare but desirable maturation pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolutionary trees from DNA sequences: A maximum likelihood approach.
Felsenstein, J. (1981) · Journal of Molecular Evolution · doi:10.1007/bf01734359 · Cited by 14,571
Follicular Helper CD4 T Cells (T FH )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738
Antibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Predominant Autoantibody Production by Early Human B Cell Precursors
Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., & Nussenzweig, M. C. (2003) · Science · doi:10.1126/science.1086907 · Cited by 2,083
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Clonal selection and learning in the antibody system
Rajewsky, K. (1996) · Nature · doi:10.1038/381751a0 · Cited by 1,709
Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow.
Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D., & Hayakawa, K. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.5.1213 · Cited by 1,601
Smith, G. P., & Petrenko, V. A. (1997) · Chemical Reviews · doi:10.1021/cr960065d · Cited by 1,548
Cited by
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Self-citationBroad and potent neutralization of HIV-1 by a gp41-specific human antibody
Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Bailer, R. T., Chakrabarti, B., Sharma, S. K., et al. (2012) · Nature · doi:10.1038/nature11544 · Cited by 828
Self-citationRational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
HIV-1 neutralizing antibodies induced by native-like envelope trimers
Sanders, R. W., van Gils, M. J., Derking, R., Sok, D., Ketas, T. J., Burger, J. A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. (2015) · Science · doi:10.1126/science.aac4223 · Cited by 496
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & De Gregorio, E. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 435
Tam, H. H., Melo, M. B., Kang, M., Pelet, J. M., Ruda, V. M., Foley, M. H., Hu, J. K., Kumari, S., Crampton, J., Baldeon, A. D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606050113 · Cited by 425
Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
Jardine, J. G., Ota, T., Sok, D., Pauthner, M., Kulp, D. W., Kalyuzhniy, O., Skog, P. D., Thinnes, T. C., Bhullar, D., Briney, B., et al. (2015) · Science · doi:10.1126/science.aac5894 · Cited by 420
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies
Steichen, J. M., Kulp, D. W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R. L., McCoy, L. E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.016 · Cited by 401
Liao, H.-X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K.-K., Chen, X., Tsao, C.-Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.011 · Cited by 377
Self-citationA Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 375
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Self-citationde Taeye, S. W., Ozorowski, G., Torrents de la Peña, A., Guttman, M., Julien, J.-P., van den Kerkhof, T. L. G. M., Burger, J. A., Pritchard, L. K., Pugach, P., Yasmeen, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.056 · Cited by 338
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice
Escolano, A., Steichen, J. M., Dosenovic, P., Kulp, D. W., Golijanin, J., Sok, D., Freund, N. T., Gitlin, A. D., Oliveira, T., Araki, T., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.030 · Cited by 320
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M. G., Ozorowski, G., Chuang, G.-Y., Schramm, C. A., Wiehe, K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.022 · Cited by 319
Self-citationHIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
Kwong, P. D., & Mascola, J. R. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.029 · Cited by 304
Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination
Palm, A.-K. E., & Henry, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01787 · Cited by 288
Accelerating Next-Generation Vaccine Development for Global Disease Prevention
Koff, W. C., Burton, D. R., Johnson, P. R., Walker, B. D., King, C. R., Nabel, G. J., Ahmed, R., Bhan, M. K., & Plotkin, S. A. (2013) · Science · doi:10.1126/science.1232910 · Cited by 282
Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies
Gao, F., Bonsignori, M., Liao, H.-X., Kumar, A., Xia, S.-M., Lu, X., Cai, F., Hwang, K.-K., Song, H., Zhou, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.022 · Cited by 279
Self-citationVaccination induces HIV broadly neutralizing antibody precursors in humans
Leggat, D. J., Cohen, K. W., Willis, J. R., Fulp, W. J., deCamp, A. C., Kalyuzhniy, O., Cottrell, C. A., Menis, S., Finak, G., Ballweber-Fleming, L., et al. (2022) · Science · doi:10.1126/science.add6502 · Cited by 276
Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
Bonsignori, M., Kreider, E. F., Fera, D., Meyerhoff, R. R., Bradley, T., Wiehe, K., Alam, S. M., Aussedat, B., Walkowicz, W. E., Hwang, K.-K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7514 · Cited by 270
Self-citationTailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
Briney, B., Sok, D., Jardine, J. G., Kulp, D. W., Skog, P., Menis, S., Jacak, R., Kalyuzhniy, O., de Val, N., Sesterhenn, F., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.005 · Cited by 255
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Eliciting B cell immunity against infectious diseases using nanovaccines
Singh, A. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00790-3 · Cited by 169
Nguyen, H. T., Wang, Q., Anang, S., & Sodroski, J. G. (2023) · Journal of Virology · doi:10.1128/jvi.01857-22 · Cited by 19
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
del Moral-Sánchez, I., Wee, E. G., Xian, Y., Lee, W.-H., Allen, J. D., Torrents de la Peña, A., Fróes Rocha, R., Ferguson, J., León, A. N., Koekkoek, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00862-8 · Cited by 14
Capella-Pujol, J., de Gast, M., Radić, L., Zon, I., Chumbe, A., Koekkoek, S., Olijhoek, W., Schinkel, J., van Gils, M. J., Sanders, R. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39690-0 · Cited by 12
(2026) · doi:10.1073/pnas.2532810123 · Cited by 8
Metadata
- Authors
- Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B.
- Venue
- Nature Biotechnology
- Published
- 2012-05
- Volume
- 30
- Issue
- 5
- Pages
- 423-433
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1969156908
- Cited by
- 486
- References
- 138
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.